|Rockwell Medical, Inc.|
30142 Wixom Road
United States - Map
Rockwell Medical, Inc. operates as an integrated biopharmaceutical company in the United States and internationally. It offers products and services for the treatment of end-stage renal disease, chronic kidney disease, iron deficiency, secondary hyperparathyroidism, and hemodialysis. The companys products are used to cleanse patients' blood and replace nutrients lost during the kidney dialysis process. It primarily markets Triferic, an iron compound that is delivered to hemodialysis patients via dialysate, replacing the ongoing iron loss that occurs during their dialysis treatment. The company also provides Calcitriol, a generic active vitamin D indicated for the treatment of secondary hyperparathyroidism in dialysis patients. In addition, it manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric-acid concentrate, Dri-Sate dry acid concentrate, Renal Pure liquid acid concentrate, dry acid concentrate mixer, Renalpure powder bicarbonate concentrate, and SteriLyte liquid bicarbonate concentrate; and ancillary products, including blood tubings, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company sells its products directly, as well as through independent sales agents and distributors. It targets customers include senior and operating management of dialysis companies, dialysis service providers, nephrologists, clinic administrators, nurses, medical directors, and purchasing personnel. Rockwell Medical, Inc. was founded in 1995 and is based in Wixom, Michigan.
|Rockwell Medical, Inc.’s ISS Governance QuickScore as of Apr 1, 2016 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 6; Compensation: 10.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Robert L. Chioini ,
Founder, Chairman of The Board and Chief Exec. Officer
|Mr. Thomas E. Klema CPA, MBA,
Chief Financial Officer, VP of Fin., Treasurer and Sec.
|Dr. Ajay Gupta M.D.,
Chief Scientific Officer and Member of Scientific Advisory Board
|Dr. Raymond Dennis Pratt M.D., FACP,
Chief Medical Officer
|Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|